Evidence map›Paper›PMID 37123424›Full record

ArticleMiddle East African journal of ophthalmology

Comparison of Glaucoma Therapy Escalation After Penetrating Keratoplasty to Descemet Stripping Automated Endothelial Keratoplasty for the Treatment of Pseudophakic Bullous Keratopathy: A Cohort Study.

Abdulrahman Aldarrab, Wael Alsakran, Samar A Al-Swailem, Sami A Al-Shahwan

Open access · hybridAbstract read
In one paragraph

Article in Middle East African journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Abdulrahman AldarrabDepartment of Surgery, College of Medicine, Prince Sattam Bin Abdulaziz University, AlKharj, Saudi Arabia.
Wael AlsakranRetina Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Samar A Al-SwailemAnterior Segment Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Sami A Al-ShahwanGlaucoma Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
King Khaled Eye Specialist Hospital · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to compare glaucoma therapy escalation (GTE), graft survival, vision, and glaucoma following penetrating keratoplasty (PK group) and Descemet stripping automated endothelial keratoplasty (DSAEK group) to treat pseudophakic bullous keratopathy (PBK).

methodsThis cohort included cases of PBK managed with PK from 2009 to 2014. We compared the incidences and determinants of GTE, graft survival, and visual disability.

resultsThere were 58 eyes in the PK group and 117 eyes in the DSAEK group. The incidence of GTE in the PK and DSAEK groups at the last follow-up was 34.2% (95% confidence interval [CI]: 19.5-48.9) and 46.6% (95% CI: 27.7-65.4), respectively. The risk of GTE was similar between the groups (relative risk [RR] = 1.36 [95% CI: 0.94-1.98],

conclusionGTE was similar in eyes with PBK managed by PK or DSAEK. Glaucoma and previous keratoplasty were predictors of GTE post-keratoplasty. DSAEK gave better visual outcomes than PK for managing PBK.

Indexed as

Corneal DiseasesCorneal EdemaDescemet Stripping Endothelial KeratoplastyGlaucomaCohort StudiesEndothelium, CornealGraft SurvivalHumansKeratoplasty, PenetratingRetrospective StudiesVisual AcuityDescemet stripping automated endothelial keratoplastyglaucoma therapy escalationgraft failurepenetrating keratoplastypseudophakic bullous keratopathy

Identifiers

PMID37123424
PMCPMC10138129
OpenAlexW4321846683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.